- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo
- Drug
- Lead sponsor
- Mycovia Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Encino, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced May 22, 2026, 2:49 AM EDT